Intervention in utero: Fetal gene therapy

In Utero Fetal Surgery

INSTRUCTIONS FOR USE This Medical Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the enrollee specific document must be referenced. The terms of an enrollee's document (e.g., Certificate of Coverage (COC) or Summary Plan Description (SPD) and Medicaid State Contracts) may differ greatly from the standard benefit plans upon which this Medical P...

Fetal Gene Therapy

Researchers seek guidance on "preproposal" for in utero gene therapy.

Despite all this promising work, some epidemiological data comparing tea drinkers and non-tea drinkers does not support the claim that tea prevents cancer. One study even found tea drinkers have higher cancer rates than nontea drinkers; two others showed no tea effects. Difficulties sorting out possible confounding factors, such as other diet and health-related habits , may continue to hinder s...

Long term physiologic modification using rAAV in utero gene-therapy

BACKGROUND: Transfer of genes in utero via the amniotic fluid was shown previously with recombinant adeno-associated viruses (rAAV) to be highly efficient. Expression for over one year was demonstrated using reporter genes. In addition, it was shown previously that transgenes delivered by this method release protein into the general circulation. Given these results experiments were designed to ...

Clinical Policy Title: Fetal surgery in utero

ABOUT THIS POLICY: AmeriHealth Caritas District of Columbia has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas District of Columbia’s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical spe...